Toronto Sunnybrook Regional Cancer Centre
10
0
2
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 10 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Stereotactic Body Radiation Therapy for Breast Cancer
Role: lead
Prostate Screening Study Using MRI in BRCA Carriers
Role: lead
Intratympanic N-Acetylcysteine for Prevention of Cisplatin-induced Ototoxicity.
Role: collaborator
Concordance Between Liquid and Tissue Biopsy
Role: collaborator
Stereotactic Body Radiotherapy for Patients With Breast Cancer Oligometastasis
Role: collaborator
The Prone Breast Radiation Therapy Trial
Role: lead
Reducing Sedentary Behavior Among Prostate Cancer Survivors on Androgen Deprivation Therapy
Role: collaborator
Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma
Role: lead
Response of Patients on Surveillance for Prostate Cancer to Dutasteride
Role: collaborator
Role of PET CT in Determining Target Volumes in Radiation Therapy for Lung Cancer
Role: lead
All 10 trials loaded